Pasithea Therapeutics Corp. (KTTA): Shareholders' Equity
$55.22M
As of 2025-12-31
$49.84M
As of 2026-06-30
+9.1%
3-year compound annual growth
n/m
5-year compound annual growth
| Period ended | Shareholders' Equity | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $55.22M | +273.5% | 2026-03-30, Balance as of period end |
| 2024-12-31 | $14.78M | -36.8% | 2026-03-30, Balance as of period end |
| 2023-12-31 | $23.40M | -44.9% | 2025-03-24, Balance as of period end |
| 2022-12-31 | $42.50M | -17.4% | 2024-03-29, Balance as of period end |
| 2021-12-31 | $51.42M | n/m | 2023-03-30, Balance as of period end |
| 2020-12-31 | $241.4K | n/a | 2022-03-30, Balance as of period end |
Shareholders' Equity at similar companies
| Company | Year ended | Shareholders' Equity | Change YoY |
|---|---|---|---|
| Pasithea Therapeutics Corp. (KTTA) | 2025-12-31 | $55.22M | +273.5% |
| ProPhase Labs, Inc. (PRPH) | 2025-12-31 | $3.51M | -52.3% |
| Palvella Therapeutics, Inc. (PVLA) | 2025-12-31 | $27.98M | -55.3% |
| DiaMedica Therapeutics Inc. (DMAC) | 2025-12-31 | $56.11M | +37.8% |
| ALX Oncology Holdings Inc (ALXO) | 2025-12-31 | $25.98M | -77.1% |
| Scynexis Inc (SCYX) | 2025-12-31 | $49.38M | -10.4% |
| Q32 Bio Inc. (QTTB) | 2025-12-31 | $42.01M | +640.3% |
| Rani Therapeutics Holdings, Inc. (RANI) | 2025-12-31 | $33.01M | n/m |
| AN2 Therapeutics, Inc. (ANTX) | 2025-12-31 | $53.06M | -35.2% |
Compare KTTA, PRPH, PVLA, DMAC side by side · Screen every company in Pharmaceutical Preparations ↗